Vinge advises Nuevolution AB (publ) in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market.
The prospectus was published on 20 June 2018 and the trading on Nasdaq Stockholm commenced on 25 June 2018.
Nuevolution AB (publ) is a small molecule drug discovery biotech company. The company was founded in 2001 and is headquartered in Copenhagen, Denmark.
Vinge’s team has primarily consisted of Dain Hård Nevonen, David Andersson, Maria Schultzberg, Nils Fredrik Dehlin, Malte Hedlund, Anna Thoms, Klara Secher and Victor Ericsson.